X0306 4 2021-07-22 0 0001831915 Cytek Biosciences, Inc. CTKB 0001165399 DENG FENG 2855 SAND HILL ROAD MENLO PARK CA 94025 1 0 0 0 Common Stock 2021-07-22 4 C 0 147933 A 147933 I See footnote Common Stock 2021-07-22 4 C 0 4168777 A 4168777 I See footnote Common Stock 2021-07-22 4 C 0 443800 A 443800 I See footnote Series A Preferred Stock 2021-07-22 4 C 0 147933 0.00 D Common Stock 147933 0 I See footnote Series C Preferred Stock 2021-07-22 4 C 0 4168777 0.00 D Common Stock 4168777 0 I See footnote Series D Preferred Stock 2021-07-22 4 C 0 443800 0.00 D Common Stock 443800 0 I See footnote Each share of Preferred Stock automatically converted on a one-for-one basis into Common Stock upon the closing of the Issuer's initial public offering (the "IPO"), for no additional consideration. The shares of Preferred Stock have no expiration date. Shares held directly by Northern Light Venture Capital V, Ltd. ("NLVC V"). Fund V serves as the nominee for each of Northern Light Venture Fund V, L.P., Northern Light Strategic Fund V, L.P. and Northern Light Partners Fund V, L.P (together, the "NLVC V Funds"). Northern Light Partners V, L.P., a Cayman Islands exempted limited liability partnership, is the general partner of the NLVC V Funds. NLVC V is the general partner of Northern Light Partners V, L.P. Feng Deng is the controlling shareholder of NLVC V and may be deemed to have voting and dispositive power with respect to the shares held by NLVC V. /s/ Valerie Barnett, Attorney-in-Fact for Feng Deng 2021-07-27